Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The short stature homeobox protein (SHOX) is a transcription factor encoded by the SHOX gene, located in the pseudoautosomal region of both the X and Y chromosomes. SHOX helps control the expression of other genes, particularly during early embryonic development, where it is essential for normal skeletal formation and the growth/maturation of bones, especially in the arms and legs. It maintains bone progenitor cell populations and regulates the timing of osteogenic differentiation. Mutations, deletions, or dosage changes in SHOX lead to several congenital disorders, notably Turner syndrome, Léri-Weill dyschondrosteosis, Langer mesomelic dysplasia, and idiopathic short stature. SHOX is a member of the homeobox gene family and acts as a transcriptional activator or repressor depending on the cellular context. No clinically approved drugs directly target SHOX, and its primary relevance is as a diagnostic biomarker for skeletal dysplasia syndromes. Its therapeutic targeting, safety issues, and mechanism of action for drugs are currently not applicable given its role.
Not applicable; no known drugs directly target SHOX.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Short stature homeobox protein (SHOX).